NuVasive (NUVA) Getting Somewhat Favorable News Coverage, Accern Reports
Headlines about NuVasive (NASDAQ:NUVA) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuVasive earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 45.7373630339336 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of NuVasive, Inc. Investors … – Business Wire (press release) (businesswire.com)
- NuVasive, Inc. (NUVA) Given “Buy” Rating at Gabelli (americanbankingnews.com)
- Analyst: Hurricanes Harvey, Irma, Maria expected to have impact on med device revenue (massdevice.com)
- Law Offices of Howard G. Smith Commences Investigation on Behalf of NuVasive, Inc. Investors (NUVA) (4-traders.com)
- Arons & Arons, LLC. Announces Investigation on Behalf of NuVasive, Inc. Investors (finance.yahoo.com)
A number of equities research analysts have recently issued reports on NUVA shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $88.00 target price (up previously from $84.00) on shares of NuVasive in a report on Tuesday, July 25th. Needham & Company LLC lowered shares of NuVasive from a “hold” rating to an “underperform” rating in a report on Monday, August 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $90.00 target price on shares of NuVasive in a report on Wednesday, July 5th. Leerink Swann reaffirmed a “buy” rating and set a $74.00 target price (down previously from $87.00) on shares of NuVasive in a report on Wednesday, September 20th. They noted that the move was a valuation call. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $90.00 target price (up previously from $85.00) on shares of NuVasive in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $79.92.
NuVasive (NUVA) opened at 56.17 on Thursday. The firm has a market cap of $2.85 billion, a PE ratio of 88.46 and a beta of 1.08. The firm has a 50-day moving average of $62.55 and a 200-day moving average of $71.98. NuVasive has a 52-week low of $52.85 and a 52-week high of $81.68.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The firm had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. During the same quarter last year, the business posted $0.40 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts anticipate that NuVasive will post $2.00 EPS for the current year.
In other NuVasive news, CEO Gregory T. Lucier purchased 5,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were purchased at an average cost of $66.22 per share, with a total value of $331,100.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Gregory T. Lucier purchased 2,000 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was acquired at an average cost of $61.52 per share, for a total transaction of $123,040.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 14,850 shares of company stock worth $955,598. 1.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “NuVasive (NUVA) Getting Somewhat Favorable News Coverage, Accern Reports” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/28/nuvasive-nuva-getting-somewhat-favorable-news-coverage-accern-reports.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.